Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received bortezomib in combination with lenalidomide and dexamethasone as first line of therapy in the united states

HIGHLIGHTS

• who: Rohan Medhekar from the in the United States have published the Article: Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and dexamethasone as first line of therapy in the United States, in the Journal: (JOURNAL) of February/28,/2021
• what: The aim of this study was to evaluate patient characteristics and treatment outcomes (PFS and time-to-next- treatment) among NDMM patients who received VRd as first LOT in the authors oncology practice settings. Contrary to observations from phase 1 and phase 2 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.